Business Context and Reporting Period
Company: Recursion Pharmaceuticals, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: January 10, 2022
Event: Regulation FD Disclosure regarding the release of an updated investor presentation intended for use at the JP Morgan Healthcare meeting and in investor meetings.
Key Financial Metrics
This filing does not contain specific financial data. The document serves as a disclosure of an attached investor presentation (Exhibit 99.1) but does not report revenue, profit, cash flow, margins, debt, or liquidity figures within the text of the 8-K itself.
Material Changes
No material financial changes or operational updates are detailed in the text of this filing. The sole material event is the distribution of new non-filed information via an investor presentation.
Guidance, Outlook, and Risks
Management Commentary: The company released an updated investor presentation to be used at the JP Morgan Healthcare meeting.
Legal Status of Information: The information furnished pursuant to Item 7.01, including the attached presentation, is not deemed "filed" under Section 18 of the Securities Exchange Act of 1934. It is not subject to the liabilities of that section and is not incorporated by reference into other filings unless expressly stated.
Risks: No specific risks or contingencies are listed in this filing text.
Investor Verification Checklist
- Review the attached Exhibit 99.1 (Investor Presentation) for specific financial projections, pipeline updates, and strategic outlook, as these details are not in the 8-K text.
- Confirm that the information in the presentation is not considered "filed" for liability purposes under the Exchange Act.
- Verify the company's status as an Emerging Growth Company (indicated as checked in the filing).
- Check subsequent filings (e.g., 10-K or 10-Q) for audited or reviewed financial statements corresponding to the period discussed in the presentation.